Data as of Sep 19
| +0.05 / +1.89%|
Alexza Pharmaceuticals, Inc. is a pharmaceutical company, which is focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system, or CNS, conditions. The company's product candidates are based on its proprietary technology, the Staccato system. Its lead product candidate is ADASUVE, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder. The company's other product candidates, which are in clinical stage includes AZ-007, Staccato nicotine, AZ-10, AZ-002 and AZ-002. It was formerly known as Alexza Molecular Delivery Corp. and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals was founded by Alejandro C. Zaffaroni on December 19, 2000 and is headquartered in Mountain View, CA.
|Thomas Braxton King||President, Chief Executive Officer & Director|
|Robert A. Lippe||Chief Operations Officer & Executive VP-Operations|
|Mark K. Oki||Chief Financial Officer, Secretary, CAO & SVP|
|James V. Cassella||CSO, Executive VP-Research & Development|
|Tatjana Naranda||VP-Business Development & Alliance Management|